Ochoa, JP;
Lopes, LR;
Pérez-Barbeito, M;
Cazón, L;
de la Torre-Carpente, MM;
Sonicheva-Paterson, N;
de Uña-Iglesias, D;
... Monserrat, L; + view all
(2020)
Deletions of specific exons of FHOD3 detected by next-generation-sequencing are associated with hypertrophic cardiomyopathy.
Clinical Genetics
, 98
(1)
pp. 86-90.
10.1111/cge.13759.
Preview |
Text (Text)
Elliott_Manuscript_review1_clean.pdf - Accepted Version Download (403kB) | Preview |
Preview |
Text (Supplementary material)
Elliott_Supplementary_material.pdf - Accepted Version Download (407kB) | Preview |
![[thumbnail of graphical_abstract.jpg]](https://discovery.ucl.ac.uk/10097605/5/graphical_abstract.jpg)  Preview |
Image
graphical_abstract.jpg - Accepted Version Download (414kB) | Preview |
![[thumbnail of Fig_1.jpg]](https://discovery.ucl.ac.uk/10097605/11/Fig_1.jpg)  Preview |
Image
Fig_1.jpg - Accepted Version Download (1MB) | Preview |
![[thumbnail of Fig_2.jpg]](https://discovery.ucl.ac.uk/10097605/16/Fig_2.jpg)  Preview |
Image
Fig_2.jpg - Accepted Version Download (516kB) | Preview |
![[thumbnail of Fig_3.jpg]](https://discovery.ucl.ac.uk/10097605/21/Fig_3.jpg)  Preview |
Image
Fig_3.jpg - Accepted Version Download (1MB) | Preview |
Abstract
Despite new strategies, such as evaluating deep intronic variants and new genes in whole-genome-sequencing studies, the diagnostic yield of genetic testing in hypertrophic cardiomyopathy (HCM) is still around 50%. FHOD3 has emerged as a novel disease-causing gene for this phenotype, but the relevance and clinical implication of copy-number-variations (CNVs) have not been determined. In this study, CNVs were evaluated using a comparative depth-of-coverage strategy by NGS in 5493 hypertrophic cardiomyopathy probands and 2973 disease-controls. We detected three symmetrical deletions in FHOD3 that involved exons 15 and 16 in three HCM families (no CNVs were detected in the control group). These exons are part of the diaphanous inhibitory domain of FHOD3 protein, considered a cluster of mutations for HCM. The clinical characteristics of the affected carriers were consistent with those reported in FHOD3 in previous studies. This study highlights the importance of performing CNV analysis systematically in NGS genetic testing panels for HCM, and reinforce the relevance of the FHOD3 gene in the disease. This article is protected by copyright. All rights reserved.
| Type: | Article |
|---|---|
| Title: | Deletions of specific exons of FHOD3 detected by next-generation-sequencing are associated with hypertrophic cardiomyopathy |
| Location: | Denmark |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/cge.13759 |
| Publisher version: | http://dx.doi.org/10.1111/cge.13759 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Cardiomyopathies, Cardiomyopathy, Hypertrophic, DNA Copy Number Variations, FHOD3 protein, human, Formins, Genetic Testing, Next-Generation Sequencing |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Clinical Science |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10097605 |
Archive Staff Only
 |
View Item |
